5-Nitroisophthalic Acid

5-Nitroisophthalic Acid
Product Description

Color : Light Yellow / White or Almost White
Form : Crystals or Crystalline Powder 

Melting Point : Not less than 260-263°C
Color of Solution : Less than GY5
Loss on Drying (%) : Not more than 0.8 


Assay by Titration: 99 - 101%





CHEMCO INNOVATIVE CHEMIE PRIVATE LIMITED

  • Country/Region:
    India
  • Founded:
    1976
  • On CPHI since:
    2024
  • Certificates:
    2
  • Employees:
    100 - 249
Company types
CMO/CDMO
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Chemical Development
Contract Manufacturer
Custom Manufacturing/Custom Synthesis
Fine Chemicals Company
Intermediates Manufacturer
Specifications
  • CAS Registry Number
    618-88-2
  • Details
    Diagnostic Imaging / Contrast Media Agent for Iohexol / Iopamidol / Iodixano
  • Selling Points
    Price; Product Performance; Reputation
  • Supplied from
    India
  • Measured In
    kilogram

CHEMCO INNOVATIVE CHEMIE PRIVATE LIMITED

  • Country/Region:
    India
  • Founded:
    1976
  • On CPHI since:
    2024
  • Certificates:
    2
  • Employees:
    100 - 249
Company types
CMO/CDMO
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Chemical Development
Contract Manufacturer
Custom Manufacturing/Custom Synthesis
Fine Chemicals Company
Intermediates Manufacturer

More Products from CHEMCO INNOVATIVE CHEMIE PRIVATE LIMITED (2)

  • 3-Acetamidophthalic Anhydride

    Product 3-Acetamidophthalic Anhydride

    Advanced Intermediate for Apremilast 
  • 2-Thiobarbituric Acid

    Product 2-Thiobarbituric Acid

    Color : White / Almost White / Light Yellow / Light Brown Form : Powder L O D (Loss on Drying) : Not more than 1% Sulphated Ash : Not more than 0.5% Foreign Matter : No Foreign Matter Assay by titration: Not less than 99% Packing : HDPE plastic drums with internal PE liners(25 Kg.Net each)

CHEMCO INNOVATIVE CHEMIE PRIVATE LIMITED resources (2)

  • News Upcoming GMP Unit for Advanced Intermediates

    Chemco is expanding its pharmaceutical manufacturing capabilities through an upcoming GMP unit dedicated to advanced and penultimate intermediates. The facility is being developed to support customer programs linked to APIs including Acalabrutinib, Ambrisentan, Apixaban, Apremilast, Canagliflozin, Chlorthalidone, Dapagliflozin, Sotagliflozin, Doxofylline, Empagliflozin, Etoricoxib, Famotidine, Ibrutinib, Mirabegron, Tazemetostat, Ticagrelor and Praziquantel.

    The new unit will support process development, technology transfer, scale-up and commercial manufacturing, with a focus on reliable execution, long-term supply and customer-specific intermediate programs.